A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.5% in the afternoon session after the stock ...

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Durban-headquartered pharmaceutical major Aspen Pharmacare confirmed in a Sens announcement on Friday that it has reached a ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Stock futures edged higher on Monday as optimism over a potential US-China trade deal and a widely expected Federal Reserve ...

Novartis is buying Avidity Biosciences for $12 billion, picking up RNA-based medicines for neuromuscular diseases as it seeks ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple ...